A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma

A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma

Refractory/relapsed B cell lymphoma patients who received the available anti-CD19 chimeric antigen receptor (CAR) T cells may still experience a short duration of remission. Here in this study, we evaluated the safety and efficacy of a novel dominant-negative programmed cell death-1 (PD-1) armored a...

Full description

Bibliographic Details
Main Authors: Xiaoqian Liu, Yuanfeng Zhang, Kaimin Li, Yinghui Liu, Junqing Xu, Junjie Ma, Licai An, Hui Wang, Xiaoxia Chu
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:Translational Oncology
Subjects:
Lymphoma
Chimeric antigen receptor T cell (CAR T cell)
Programmed cell death-1(PD-1)
Clinical trial
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523321000772

Internet

http://www.sciencedirect.com/science/article/pii/S1936523321000772

Similar Items